Skip to main content

Table 2 Diameter and maximum standardized uptake value (SUVmax) of each lesion at each timepoint in treatment with nivolumab

From: Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab

Patient Site of Lesion Baseline 1st assessment 2nd assessment
Diameter (mm) SUVmax Diameter (mm) SUVmax Response Diameter (mm) Response
1 kidney (primary) 63 7.5 65 3.7 SD 62 SD
LN 60 7.6 61 6.3   60  
lung 10 1.5 10 1.6   7  
2 bone 49 5.4 50 5.0 SD 54 PDa
lung 27 3.5 29 3.3   33  
lung 12 2.8 14 2.2   14  
3 lung 39 8.8 28 8.5 SD 18 PR
subcutaneous 13 1.9 10 1.0   4  
4 bone 65 5.9 57 4.7 SD 60 SD
adrenal 45 3.7 45 3.6   60  
bone 41 3.4 38 3.3   35  
5 subcutaneous 161 5.1 151 6.7 SD 90 PR
adrenal 38 5.1 39 6.3   21  
liver 33 4.5 38 5.4   23  
LN 15 3.4 12 3.4   0  
lung 12 5 12 5.4   12  
muscle 45 4.2 45 5.6   31  
bone 15 2.8 14 3.5   0  
subcutaneous 15 2.1 14 3.7   0  
6 lung 18 4.1 19 2.0 SD 8 PR
lung 23 3.5 20 6.3   11  
adrenal 28 2.5 28 5.1   21  
7 LN 15 3.3 15 2.9 SD 6 PR
lung 36 4.8 36 4.2   17  
8 lung 22 5.1 17 6.1 SD 10 SD
lung 17 2.2 14 3.0   5  
adrenal 32 3.7 34 2.8   41  
9 lung 42 4.0 34 3.4 SD 13 PR
LN 16 4.8 10 3.0   8  
LN 15 3.4 15 3.2   15  
  1. PR Partial response, SD Stable disease, PD Progressive disease
  2. aPD: appearance of new lesion